TEST:

Xpert HPV Assay

P=N/A, N=8445, Not yet recruiting, Tulane University | Trial completion date: Jan 2031 --> Aug 2028 | Trial primary completion date: Jan 2031 --> Jun 2028

The study provides a more nuanced understanding of HPV prevalence in Ecuador, indicating that HPV rates are lower than previous national studies but higher than global estimates. The results lay essential groundwork for targeted public health interventions and suggest the need for future research to address methodological limitations.

P=N/A, N=500, Active, not recruiting, University Hospital, Geneva

P=N/A, N=1002, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Jul 2026 --> Jul 2025

Unemployment was associated with increased odds of hrHPV among the study participants. This calls for extended HPV genotyping during screening and customization of HPV vaccination to cover all HPV genotypes.

This study demonstrated a high accuracy of the Xpert-HPV test for HR-HPVs detection and genotyping in FFPE CC tissues and revealed a distinct distribution of HR-HPVs in Tunisia.

Although genotype-specific risks require confirmation, the data align with emerging evidence that HPV infection itself-not only post-treatment cervical changes-may promote spontaneous PTB. If corroborated, these findings extend the public-health value of HPV vaccination beyond cancer prevention and support closer obstetric surveillance of hr-HPV-positive pregnancies.

P=N/A, N=1002, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting

Using more stringent Ct cutoffs on the three channels that detect the eight highest-risk HPV types can improve the sensitivity-specificity balance of a round of screening in both self- and clinician-collected samples. Although performance of HPV testing on self-collected samples is excellent, performance parameters are better on clinician-collected samples.

Its integration into primary cervical cancer screening programs could significantly enhance the early detection of HPV-positive cases, thereby strengthening the screening framework and potentially reducing both the incidence and mortality of cervical cancer. Future studies should focus on confirming these results and exploring the utility of this method in conjunction with other diagnostic tools such as visual inspection with acetic acid (VIA) for a comprehensive assessment of its effectiveness in real-world settings.

HR-HPV prevalence was high among Mozambican women aged 30-49 years, especially among WLWH, consistent with the high burden of cervical cancer in this population. HPV16 was the most common HR-HPV group among women with cervical cancer. Further study is needed to determine the role of HR-HPV genotyping in follow-up and treatment in Mozambique.

P=N/A, N=1000, Recruiting, Weill Medical College of Cornell University | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Jan 2025 --> Jul 2026